RDD Pharma is a specialty pharmaceutical company focused on fast-track development and commercialization of therapeutics for anorectal diseases and lower-gastrointestinal tract disorders. The company has two clinical-stage products: RDD-1219 for chronic anal fissure, currently enrolling patients in a multicenter European Phase 3 study with 300 patients already enrolled, and RDD-0315 for fecal incontinence, an indication with no approved prescription products. Two pre-clinical assets target pruritus ani and radiation colitis/proctitis. Led by CEO Jason Laufer, the company is based in New York and Tel Aviv. RDD Pharma intends to use the funds to advance its programs globally in anal fissure, fecal incontinence, radiation colitis/proctitis and pruritus ani. The company recently completed a Series B financing to support these plans.

Total raised

$10M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2017